[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-365719-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-365719-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","effective-car-t-cell-targeting-of-an-muc1-cleavage-product","Effective CAR T-cell targeting of an MUC1 cleavage product","","Background: Chimeric antigen receptor (CAR) T cells were engineered to target mucin 1 (MUC1*), using antibody MNC2 that binds MUC1* on cancer cells without binding full-length MUC1 on normal epithelial cells. CD3ζ Tyr to Phe mutations (“1XX”) were evaluated for improved persistence and activity against low-antigen-expressing tumors. Methods: In vivo comparisons tested CARs with 4-1BB or CD28 co-stimulation and with or without 1XX mutations, using xenograft models with graded antigen expression. Results: High-dose CARs killed high-antigen tumors short term, but only 1XX CARs prevented long-term recurrence and eradicated low-antigen tumors even at low dose. Conclusions: Combining MUC1* targeting with 1XX CAR T design supports therapeutic potential for solid tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/effective-car-t-cell-targeting-of-an-muc1-cleavage-product/365719/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/effective-car-t-cell-targeting-of-an-muc1-cleavage-product/365719.png","ImageObject",300,407,{"name":42,"@type":43},"Alex Sinclair","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main tumor target used for the CAR T cells in this study?","Question",{"text":63,"@type":64},"The CAR T cells target mucin 1 (MUC1*), a growth-factor-receptor form of MUC1 on cancer cells, using the antibody MNC2.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were CARs designed to test persistence and killing of low-antigen tumors?",{"text":68,"@type":64},"CARs were compared with either 4-1BB or CD28 co-stimulatory domains and with or without CD3ζ “1XX” Tyr-to-Phe mutations in ITAMs 2 and 3.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the key findings about tumor recurrence and antigen sensitivity?",{"text":72,"@type":64},"At high dose, all CARs killed high-antigen tumors short term, but only the 1XX CAR inhibited recurrence long term and could kill low-antigen-expressing tumors even at low dose.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},365719,1790350420,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open access Original research  \nEffective CAR T-cell targeting of an MUC1 cleavage product  \nBenoit J Smagghe,1 Mark G Carter,1 Kevin R Yi  ,1 Jac-Leen S S Nash,1 Trevor J Grant,1 Dan S Miller,1 Scott T Moe,1 David D Smith,2 Michael J Nash,1 Natalie K Miller,1 Laura L Agarkov,1 Jacy P Marquez,1 Andrew K Stewart,1 Cynthia C Bamdad1  \nTo cite: Smagghe BJ,  \nCarter MG, Yi KR, et al. Effective CAR T-cell targeting of an MUC1 cleavage product. Journal for ImmunoTherapy of Cancer 2025;13:e010577 . doi:10 . 1136/ jitc-2024-010577  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2024-010577](jitc-2024-010577)) .  \nBJS and MGC contributed equally.  \nAccepted 13 May 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Minerva Biotechnologies Corporation, Waltham, Massachusetts, USA 2Mercy Lab Foundation, Pasadena, California, USA  \nCorrespondence to  \nDr Cynthia C Bamdad; [cbamdad@minervabio.com](cbamdad@minervabio.com)  \nABSTRACT  \nBackground We developed Chimeric antigen receptor (CAR) T cells targeting mucin 1 (MUC1)* (muk * (muk 1 star)), which is the tumor-associated growth factor receptor form of MUC1 . Our antibody, MNC2, uniquely binds to MUC1* on cancer cells but does not bind to fulllength MUC1, which is expressed on all normal epithelial cells. We tested the ability of the Tyr to Phe mutations in CD3ζ, known as “1XX”, to increase in vivo persistence and enable the recognition and killing of low antigenexpressing cancer cells.  \nMethods We performed in vivo experiments comparing CARs with either 4-1BB or CD28 co-stimulatory domains, with or without the “1XX”Tyr to Phe mutations in ITAMs 2 and 3 of the CD3ζ signaling domain. All CARs were targeted to the tumor using the same huMNC2-scFv. To explore the sensitivity of each CAR, tumors comprising varying percentages of high MUC1* expressing cancer cells were xenografted. Further, wild-type low MUC1* expressing cells were engineered to fluoresce red while the cells engineered to express more MUC1* were made to fluoresce green. This experimental design allowed us to compare the sensitivity limits of the CARs against low versus high antigen-expressing cancer cells.  \nResults At high dose, all the CAR T cells effectively killed high antigen-expressing tumors in the short term. However, only the CAR bearing the 1XX mutations inhibited tumor recurrence in long-term experiments. Interestingly, in animals treated with CARs bearing wild-type CD3ζ, tumor recurrence was driven by the low antigenexpressing cells. Only the CAR bearing 1XX mutations demonstrated the ability to kill low antigen-expressing tumors, even when administered at low dose. Postsacrifice analysis showed that the CAR T cells with 1XX mutations persisted longer in vivo than either 4-1BB or CD28 CAR T cells with wild-type CD3ζ .  \nConclusions These results support that the combination of targeting MUC1*, the growth factor receptor form of MUC1, with a CAR T bearing the 1XX mutations in CD3ζ has therapeutic potential for the treatment of solid tumor cancers.  \nINTRODUCTION  \nMucin 1 (MUC1), a single pass type I transmembrane protein, has long been an attractive target for cancer therapeutics because it is aberrantly expressed on about 75% of  \nWHAT IS ALREADY KNOWN ON THIS TOPIC  \n\n| ⇒ A dearth of suitable cell surface targets hinders the development of successful CAR T-cell therapy for the treatment of solid tumor cancers.\u003Cbr>⇒ Current CAR T cells may not persist long enough, be sensitive enough, or maintain enough effector function to successfully treat solid tumor cancers.\u003Cbr>WHAT THIS STUDY ADDS |\n| --- |\n| ⇒ We describe a new target, mucin 1 (MUC1)*, for the treatment of solid tumor cancers. We compared the efficacy, persistence and antigen sensitivity of three CARs, all dire","cbCaios07HKqkqNq","https://ap.wps.com/l/cbCaios07HKqkqNq","pdf",5561893,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# What is already known on this topic\n# What this study adds\n# How this study might affect research, practice or policy","[{\"question\":\"What is the main tumor target used for the CAR T cells in this study?\",\"answer\":\"The CAR T cells target mucin 1 (MUC1*), a growth-factor-receptor form of MUC1 on cancer cells, using the antibody MNC2.\"},{\"question\":\"How were CARs designed to test persistence and killing of low-antigen tumors?\",\"answer\":\"CARs were compared with either 4-1BB or CD28 co-stimulatory domains and with or without CD3ζ “1XX” Tyr-to-Phe mutations in ITAMs 2 and 3.\"},{\"question\":\"What were the key findings about tumor recurrence and antigen sensitivity?\",\"answer\":\"At high dose, all CARs killed high-antigen tumors short term, but only the 1XX CAR inhibited recurrence long term and could kill low-antigen-expressing tumors even at low dose.\"}]","Effective CAR T-cell targeting of an MUC1 cleavage product | PDF",1790161990,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/df393dd6842f41462a559cf9ea19cc6f.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3516447a4f68e954ef32e2b528875d5c.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bea25d5857efb0f9626a30d8d38ef8c4.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05cee1ebe33c4735cc035efec08aa648.webp",980,1306]